WO1988000944A1 - Derives de thiazole - Google Patents

Derives de thiazole Download PDF

Info

Publication number
WO1988000944A1
WO1988000944A1 PCT/JP1987/000166 JP8700166W WO8800944A1 WO 1988000944 A1 WO1988000944 A1 WO 1988000944A1 JP 8700166 W JP8700166 W JP 8700166W WO 8800944 A1 WO8800944 A1 WO 8800944A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl group
general formula
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1987/000166
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Kenichi Kanai
Kiyoto Goto
Kinji Hashimoto
Yoshiaki Tsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Original Assignee
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Otsuka Pharmaceutical Factory Inc filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP62-501805A priority Critical patent/JPH0662413B2/ja
Priority to GB8807032A priority patent/GB2203146B/en
Publication of WO1988000944A1 publication Critical patent/WO1988000944A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
    • C10M105/00—Lubricating compositions characterised by the base-material being a non-macromolecular organic compound
    • C10M105/08—Lubricating compositions characterised by the base-material being a non-macromolecular organic compound containing oxygen
    • C10M105/32—Esters
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
    • C10M111/00—Lubrication compositions characterised by the base-material being a mixture of two or more compounds covered by more than one of the main groups C10M101/00 - C10M109/00, each of these compounds being essential
    • C10M111/04—Lubrication compositions characterised by the base-material being a mixture of two or more compounds covered by more than one of the main groups C10M101/00 - C10M109/00, each of these compounds being essential at least one of them being a macromolecular organic compound
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
    • C10M169/00—Lubricating compositions characterised by containing as components a mixture of at least two types of ingredient selected from base-materials, thickeners or additives, covered by the preceding groups, each of these compounds being essential
    • C10M169/04—Mixtures of base-materials and additives

Definitions

  • R 3 represents a hydrogen atom or ⁇ Cs
  • Lubazol group carboxyl group, carboxy-Ci ⁇
  • R 14 is shows the hydrogen atoms' child, -C S alkyl group, full Eniru group or inhibit Dorokishi Ci ⁇ Gs alkyl group.
  • the compound of the present invention obtained by the reaction shown in each of the above reaction schemes can be easily isolated and purified by a separation means for chemicals.
  • the separating means include a solvent oil removal method, a recrystallization method, and column chromatography.
  • carriers such as lactose, Excipients such as sucrose, sodium chloride, pudose, urea, starch, carbonated calcium carbonate, kaolin, microcrystalline cellulose, caicic acid, etc., water, ethanol, propanol, simple syrup, sucrose solution, starch Liquid, gelatin solution, ruboxime Potassium Le cellulose, shellac, methylation cellulose,-phosphate, binding agents such as poly Binirupirori de down, dry starch, alginic acid Na Bok Liu ⁇ , agar powder, laminaran powder, sodium hydrogen carbonate Na Bokuri um, carbonate Disintegrators such as 2 ⁇ calcium, poly-xylethylene sorbitan fatty acid ester, sodium lauryl sulfate, monoglyceride stearate, starch, lactose, sucrose, stealine, cocoa butter, hydrogenated Disintegration inhibitors, quaternary ammonium bases, absorption enhancers such as sodium lau
  • compositions may include i *, Neissen's pharmaceuticals.
  • the amount of the compound of the present invention to be contained in the pharmaceutical preparation of the present invention is not particularly limited and may be appropriately selected over a wide range, but is usually preferably from 7 to 70% by weight in the pharmaceutical preparation. ⁇
  • Table 3 shows the physical properties.
  • Table 4 shows the properties of these compounds.
  • the number of viable cells was determined by staining dead cells with Tripan blue and subtracting them, and counting them using a hemocytometer.
  • the cell concentration was prepared at 3 X 1 ⁇ 3 cells Z Ueru such that ⁇ 0? / 0 FBS pressurized DME. Thus, a cell suspension was prepared.
  • the concentration of the test substance is serially doubled from 10 gzmfi.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PCT/JP1987/000166 1986-08-04 1987-03-17 Derives de thiazole Ceased WO1988000944A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP62-501805A JPH0662413B2 (ja) 1987-03-17 血管新生阻害剤
GB8807032A GB2203146B (en) 1986-08-04 1987-03-17 Thiazole derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61183873A JPS6339868A (ja) 1986-08-04 1986-08-04 ジ低級アルキルフエノ−ル誘導体
JP61/183873 1986-08-04

Publications (1)

Publication Number Publication Date
WO1988000944A1 true WO1988000944A1 (fr) 1988-02-11

Family

ID=16143319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1987/000166 Ceased WO1988000944A1 (fr) 1986-08-04 1987-03-17 Derives de thiazole

Country Status (7)

Country Link
US (1) US5104889A (https=)
EP (1) EP0275312A4 (https=)
JP (2) JPS6339868A (https=)
CH (1) CH669790A5 (https=)
DE (1) DE3790438T1 (https=)
GB (1) GB2203146B (https=)
WO (1) WO1988000944A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071865A (en) * 1989-06-14 1991-12-10 Bayer Aktiengesellschaft Pesticidal 2-acylamino-4-halogeno-5-nitrothiazoles
JP2009513566A (ja) * 2005-09-13 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２−アニリン−４−アリール置換チアゾール誘導体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011278A1 (fr) * 1989-03-24 1990-10-04 The Green Cross Corporation Composes de thiazole et leurs applications
US5102897A (en) * 1990-03-27 1992-04-07 Warner-Lambert Company 3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
WO1997047299A1 (en) * 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
DE19700795A1 (de) * 1997-01-13 1998-07-16 Bayer Ag Verwendung von Aminothiazolen zur Wund- und Hautbehandlung
US6265407B1 (en) 1997-06-24 2001-07-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting thiadiazolyl pyridazine derivatives
US6833369B2 (en) 1997-06-24 2004-12-21 Janssen Pharmaceutica, Nv Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives
ES2195374T3 (es) * 1997-06-24 2003-12-01 Janssen Pharmaceutica Nv Derivados de tiadiazolil-piridazina que impiden la angiogenesis.
TR199903082T2 (xx) * 1997-06-24 2000-07-21 Janssen Pharmaceutica N.V. Anjiogenez inhibit�r� 5-s�bstit�e-1,2,4,-tiadiazolil t�revleri.
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2336848A1 (en) * 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US7208503B2 (en) * 2000-04-21 2007-04-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
JP3836019B2 (ja) * 2001-11-21 2006-10-18 松下電器産業株式会社 受信装置、送信装置及び送信方法
UA92746C2 (en) * 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
US7408069B2 (en) 2005-08-05 2008-08-05 Bristol-Myers Squibb Company Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CA2697974C (en) 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
WO2009115547A1 (en) 2008-03-19 2009-09-24 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators
AR071763A1 (es) 2008-05-09 2010-07-14 Janssen Pharmaceutica Nv Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
JP5610351B2 (ja) 2009-03-10 2014-10-22 国立大学法人岐阜大学 チアゾール誘導体およびその製造方法
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS395907B1 (https=) * 1961-05-12 1964-04-30
JPS56120675A (en) * 1980-01-29 1981-09-22 Hoechst Ag Novel carboxylic acid derivative
JPS57175171A (en) * 1981-04-21 1982-10-28 Yamanouchi Pharmaceut Co Ltd 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compound
JPS57183767A (en) * 1981-03-18 1982-11-12 Ciba Geigy Ag Novel thiazole derivative, manufacture, pharmacological medicine containing same and use as medicine
JPS5857366A (ja) * 1981-10-02 1983-04-05 Yamanouchi Pharmaceut Co Ltd ３，５−ジ−ｔｅｒｔ−ブチル−４−ヒドロキシフエニル置換複素環化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL264710A (https=) * 1960-05-13
US3299087A (en) * 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
US3201409A (en) * 1961-04-24 1965-08-17 John D Spivack 2-substituted aminothiazoles
US3467666A (en) * 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
JPS565747B2 (https=) * 1973-10-24 1981-02-06
JPS5742629B2 (https=) * 1973-10-29 1982-09-09
JPS5537556B2 (https=) * 1973-12-27 1980-09-29
JPS5537555B2 (https=) * 1973-10-24 1980-09-29
JPS5175065A (https=) * 1974-12-06 1976-06-29 Shionogi Seiyaku Kk
JPS5833870B2 (ja) * 1976-01-12 1983-07-22 塩野義製薬株式会社 チアゾリン誘導体
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
FR2581063B1 (fr) * 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
JPS6287580A (ja) * 1985-10-14 1987-04-22 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
JPS62123180A (ja) * 1985-11-21 1987-06-04 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS395907B1 (https=) * 1961-05-12 1964-04-30
JPS56120675A (en) * 1980-01-29 1981-09-22 Hoechst Ag Novel carboxylic acid derivative
JPS57183767A (en) * 1981-03-18 1982-11-12 Ciba Geigy Ag Novel thiazole derivative, manufacture, pharmacological medicine containing same and use as medicine
JPS57175171A (en) * 1981-04-21 1982-10-28 Yamanouchi Pharmaceut Co Ltd 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compound
JPS5857366A (ja) * 1981-10-02 1983-04-05 Yamanouchi Pharmaceut Co Ltd ３，５−ジ−ｔｅｒｔ−ブチル−４−ヒドロキシフエニル置換複素環化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 81, No. 15, Abstract No. 81:91407z, 1974 (Columbus, Ohio, U.S.A.) DESHPANDE, R. N., et. al., J. Prakt. Chem., 316(2), 349 *
See also references of EP0275312A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071865A (en) * 1989-06-14 1991-12-10 Bayer Aktiengesellschaft Pesticidal 2-acylamino-4-halogeno-5-nitrothiazoles
JP2009513566A (ja) * 2005-09-13 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２−アニリン−４−アリール置換チアゾール誘導体

Also Published As

Publication number Publication date
EP0275312A1 (en) 1988-07-27
GB2203146A (en) 1988-10-12
JPH0662413B2 (ja) 1994-08-17
EP0275312A4 (en) 1988-11-14
CH669790A5 (https=) 1989-04-14
GB2203146B (en) 1991-01-23
US5104889A (en) 1992-04-14
GB8807032D0 (en) 1988-05-25
JPH0662413B1 (https=) 1994-08-17
DE3790438T1 (https=) 1988-08-25
JPS6339868A (ja) 1988-02-20

Similar Documents

Publication Publication Date Title
WO1988000944A1 (fr) Derives de thiazole
CN116444498B (zh) THRβ受体激动剂化合物及其制备方法和用途
EP2484669B1 (en) Phenol derivatives
CN103450077B (zh) IRE-1α抑制剂
JP2703408B2 (ja) １，４‐ベンゾチアゼピン誘導体
US20040248950A1 (en) Apo ai expression accelerating agent
EP1411052B1 (en) Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
JP2016040288A (ja) Ｈｅｃ１活性の調節因子およびそのための方法
JPWO1988000944A1 (ja) 血管新生阻害剤
EP3828183A1 (en) Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof
AU2004259000A1 (en) Design and synthesis of optimized ligands for PPAR
EP2907805A1 (en) Novel pyrazole derivative
AU2012345843A1 (en) Improved modulators of Hec1 activity and methods therefor
KR20210079290A (ko) 비알코올성 지방 간 질환의 치료
EP0434394A2 (en) Compounds for treating inflammatory bowel disease
EP2496230B1 (en) Ire-1 alpha inhibitors
CA3058687A1 (en) Substituted imidazole salt compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof
JPH0692360B2 (ja) 新規のベンゾセレナゾリノン化合物、これらを調製するプロセスおよびそれらを含む薬剤組成物
KR20080003924A (ko) 염기성 질소를 갖지 않는 신규 티아졸리디논, 그의 제법,및 약제로서의 그의 용도
WO2000029375A1 (en) Bisaryl compounds and cancer remedies containing the same
FR2693196A1 (fr) Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
HK40058240B (en) Thrβ receptor agonist compound and preparation method and use thereof
KR20080005971A (ko) 염기성 질소를 갖지 않는 신규 티아졸리디논, 그의 제법,및 약제로서의 그의 용도
JPH05201993A (ja) メイラード反応阻害剤
WO1990009985A1 (en) p-AMINOPHENOL DERIVATIVE AND PRODUCTION AND APPLICATION THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CH DE GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): FR

WWE Wipo information: entry into national phase

Ref document number: 1987901688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987901688

Country of ref document: EP

RET De translation (de og part 6b)

Ref document number: 3790438

Country of ref document: DE

Date of ref document: 19880825

WWE Wipo information: entry into national phase

Ref document number: 3790438

Country of ref document: DE

WWW Wipo information: withdrawn in national office

Ref document number: 1987901688

Country of ref document: EP